Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.

Run Cong Nie,Shu Qiang Yuan,Yun Wang,Xue-Bin Zou,Shi Chen,Shu Man Li,Jin ling Duan,Jie Zhou,Guo Ming Chen,Tian-Qi Luo,Zhiwei Zhou,Yuan Fang Li

Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.

2020

Run Cong Nie
Shu Qiang Yuan
Yun Wang
Xue-Bin Zou
Shi Chen
Shu Man Li
Jin ling Duan
Jie Zhou
Guo Ming Chen
Tian-Qi Luo
Zhiwei Zhou
Yuan Fang Li

Background:We assessed the surrogacy of objective response rate (ORR), disease control rate (DCR) and progression-free survival (PFS) for overall survival (OS) in anti-PD-1/PD-L1 trials of metastat...

Keywords:

programmed death 1
Pharmacology
disease control
Surrogate endpoint
Medicine
programmed death
advanced melanoma
PD-L1
overall survival
Internal medicine
Immune checkpoint
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations